183 related articles for article (PubMed ID: 15166969)
1. Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases.
Reinblatt M; Pin RH; Federoff HJ; Fong Y
Ann Surg; 2004 Jun; 239(6):892-9; discussion 899-902. PubMed ID: 15166969
[TBL] [Abstract][Full Text] [Related]
2. Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer.
Pin RH; Reinblatt M; Fong Y
Surgery; 2004 Aug; 136(2):199-204. PubMed ID: 15300180
[TBL] [Abstract][Full Text] [Related]
3. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.
Pin RH; Reinblatt M; Fong Y
Ann Surg; 2004 Oct; 240(4):659-65; discussion 665-6. PubMed ID: 15383793
[TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer.
Reinblatt M; Pin RH; Fong Y
Surgery; 2004 Sep; 136(3):579-84. PubMed ID: 15349105
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).
Kooby DA; Carew JF; Halterman MW; Mack JE; Bertino JR; Blumgart LH; Federoff HJ; Fong Y
FASEB J; 1999 Aug; 13(11):1325-34. PubMed ID: 10428757
[TBL] [Abstract][Full Text] [Related]
6. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.
Stanziale SF; Petrowsky H; Joe JK; Roberts GD; Zager JS; Gusani NJ; Ben-Porat L; Gonen M; Fong Y
Surgery; 2002 Aug; 132(2):353-9. PubMed ID: 12219034
[TBL] [Abstract][Full Text] [Related]
7. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
Jpn J Cancer Res; 2000 Dec; 91(12):1339-44. PubMed ID: 11123435
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
10. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
11. Employing tumor hypoxia for oncolytic therapy in breast cancer.
Chun YS; Adusumilli PS; Fong Y
J Mammary Gland Biol Neoplasia; 2005 Oct; 10(4):311-8. PubMed ID: 16826462
[TBL] [Abstract][Full Text] [Related]
12. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer.
Bennett JJ; Malhotra S; Wong RJ; Delman K; Zager J; St-Louis M; Johnson P; Fong Y
Ann Surg; 2001 Jun; 233(6):819-26. PubMed ID: 11371740
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.
Petrowsky H; Roberts GD; Kooby DA; Burt BM; Bennett JJ; Delman KA; Stanziale SF; Delohery TM; Tong WP; Federoff HJ; Fong Y
J Virol; 2001 Aug; 75(15):7050-8. PubMed ID: 11435585
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
17. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
18. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma.
Pin RH; Reinblatt M; Bowers WJ; Federoff HJ; Fong Y
J Gastrointest Surg; 2004 Nov; 8(7):812-22; discussion 822-3. PubMed ID: 15531234
[TBL] [Abstract][Full Text] [Related]
20. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro.
Lee JH; Federoff HJ; Schoeniger LO
J Gastrointest Surg; 1999; 3(2):127-31; discussion 132-3. PubMed ID: 10457334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
